(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,7,9-trihydroxy-N-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]-1,2,4,5,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-6-carboxamide,4-methylbenzenesulfonic acid

用途

纳得美定(S-297995)甲苯磺酸酯是一种口服活性μ-阿片受体拮抗剂(PAMORA)[1]。对重组人μ、δ和κ阿片受体而言,对甲苯磺磺酸纳地美丁表现出强大的结合亲和力(Ki分别为0.34、0.43、0.94 nM)和拮抗活性(IC50分别为25.57、7.09、16.1 nM)[2]。纳得美定可用于阿片诱导便秘(OIC)研究[2]。据预测,对甲苯磺酰纳屈定可与SARS-CoV2基因组编码的3CLpro结合[3]。
点击显示

名称

[ CAS 号 ]:
1345728-04-2

[ 英文名 ]:
(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,7,9-trihydroxy-N-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]-1,2,4,5,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-6-carboxamide,4-methylbenzenesulfonic acid

[英文别名 ]:

生物活性

[ 描述 ]:

纳得美定(S-297995)甲苯磺酸酯是一种口服活性μ-阿片受体拮抗剂(PAMORA)[1]。对重组人μ、δ和κ阿片受体而言,对甲苯磺磺酸纳地美丁表现出强大的结合亲和力(Ki分别为0.34、0.43、0.94 nM)和拮抗活性(IC50分别为25.57、7.09、16.1 nM)[2]。纳得美定可用于阿片诱导便秘(OIC)研究[2]。据预测,对甲苯磺酰纳屈定可与SARS-CoV2基因组编码的3CLpro结合[3]。

[ 相关类别 ]:

信号通路 >> G 蛋白偶联受体/G 蛋白 >> 阿片受体
研究领域 >> 代谢疾病
信号通路 >> 神经信号通路 >> 阿片受体
研究领域 >> 神经疾病

[体内研究]

甲苯磺酸纳地美定(口服灌胃；0.03-10 mg/kg；一次)通过皮下吗啡和羟考酮抑制阿片诱导的大鼠小肠转运抑制[2]。动物模型：6周龄Wistar和SD雄性大鼠[2]剂量：0.03-10mg/kg给药：灌胃；0.03-10毫克/千克；一次性结果：ED50为0.03 mg/kg,抑制皮下吗啡诱导的大鼠小肠转运抑制,ED50为1.02 mg/kg的羟考酮诱导的抑制模型。

[参考文献]

[1]. Hannah A. Blair. Naldemedine: A Review in Opioid-Induced Constipation. Drugs. 2019 Jul;79(11):1241-1247.

[2]. Toshiyuki Kanemasa, et al. Pharmacologic effects of naldemedine, a peripherally acting μ-opioid receptor antagonist, in in vitro and in vivo models of opioid-induced constipation. Neurogastroenterol Motil. 2019 May;31(5):e13563.

[3]. Sugandh Kumar, et al. Identification of multipotent drugs for COVID-19 therapeutics with the evaluation of their SARS-CoV2 inhibitory activity. Comput Struct Biotechnol J. 2021;19:1998-2017.

物理化学性质

[ 分子式 ]:
C39H42N4O9S

[ 分子量 ]:
742.83700

[ 精确质量 ]:
742.26700

[ PSA ]:
207.42000

[ LogP ]:
6.58050

推荐生产厂家/供应商：

暂无推荐供应商。请联系客服获知如何成为推荐供应商。

相关化合物

本网页内容来自不同专业数据源，如对内容有疑义，欢迎联系service1@chemsrc.com。

CAS号[1345728-04-2]化源网提供[(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,7,9-trihydroxy-N-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]-1,2,4,5,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-6-carboxamide,4-methylbenzenesulfonic acid]MSDS、说明、性质、英文名、生产厂家、作用/用途、分子量、密度、沸点、熔点、结构式等。>>电脑版：(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,7,9-trihydroxy-N-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]-1,2,4,5,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-6-carboxamide,4-methylbenzenesulfonic acid

标题：【(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,7,9-trihydroxy-N-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]-1,2,4,5,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-6-carboxamide,4-methylbenzenesulfonic acid】(4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,7,9-trihydroxy-N-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]-1,2,4,5,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-6-carboxamide,4-methylbenzenesulfonic acid CAS号:1345728-04-2【结构式 性质 活性】-化源网 地址：https://m.chemsrc.com/mip/cas/1345728-04-2_730849.html